Breakthroughs in Implantable Programmable Pump (IPP) Technology

Implantable Programmable Pumps are medical devices surgically placed under the skin to deliver controlled doses of medication directly into the body, offering targeted treatment for chronic conditions. IPPs provide customizable settings for administering various medications at different doses and timings, enabling precise remote adjustments in dosage, timing, and medication type without invasive interventions. Majorly for insulin or glucose delivery, Implantable Programmable Pumps have traditionally focused on diabetes management; however, a recent trend indicates their expanding use in delivering medications for pain relief and other therapeutic purposes, showcasing their versatile potential beyond insulin administration in the medical landscape. This shift highlights their broader applicability for targeted drug delivery in diverse medical treatments beyond glucose regulation. Let's delve deeper to know the current innovative Implantable Programmable Pump solutions within the dynamic medical device industry.

Medtronic in 2004 has innovated the SynchroMed™ II, an implantable pump that is programmable to deliver drugs to the intrathecal space via an implanted catheter. It utilizes the Control Workflow approach, strategically designed to reduce systemic opioids and ensure efficient pain relief management. Product Mechanism: The drug is pushed into the SynchroMed™ II pump reservoir via the reservoir fill port, aided by expanding gas pressure. Through peristaltic action, the pump moves the drug from the reservoir, along the tubing, catheter access port, and implanted catheter to the infusion site. Market Activity: Having a considerable share in medical device market, Medtronic maintains its leading position by various collaborations, such as the collaboration of 2014 with Mallinckrodt Pharmaceuticals. Both will co-develop and test the intrathecal products from Mallinckrodt designed for integration into Medtronic's SynchroMed® Programmable Infusion System. About Medtronic: Medtronic stands as a global leader in medical technology, fostering collaborations to address the most significant challenges in healthcare. The company has a diverse medical device portfolio, one of which is Implantable Programmable Pumps.

Prometra II by Flowonix is a Programmable Infusion Pump System. The system is permanently implanted battery-operated infusion pump. The pump is used to deliver medications directly into the cerebrospinal fluid. The device possesses Precision Dosing System that aids in micro-dosing capabilities. Further, the product received FDA PMA(S) approval on December 18, 2014. Product Mechanism: During surgery, both the infusion pump and catheter are subcutaneously implanted; typically, the pump is positioned on one side of the abdomen, near waist level, while the catheter is threaded up the spine to the intrathecal space. Subsequently, a physician uses a remote control to fill and program the implanted pump, enabling the delivery of medication. Market Activity: In 2022, Miratech Medical acquired the U.S. distribution rights to Flowonix Medical's targeted drug delivery system i.e., Prometra II designed for managing chronic pain. 1 In 2017, Flowonix Medical, Inc. and Cerebral Therapeutics, Inc. jointly developed a micro-infusion device to regulate drug delivery to a specific brain region, aimed at patients with medically resistant epilepsy. The therapy incorporates an abdominal implant of the Prometra® II Programmable Pump connected via a subcutaneous catheter to the brain. About Flowonix: Flowonix works to develop precise drug delivery platforms aimed at offering physicians an ideal solution for managing various chronic disorders in their patients. The company has a long track record in the development of pump technology.

Micro SPM-310R introduced by Primtech Corporation in 2019 is an programmable and wirelessly controlled infusion pump. The pump is implanted in laboratory animals, like mice to ensure precise and controlled flow rates. Product Mechanism: The programmable pump is subcutaneously impanted in mice and is based on a patented microprocessor controlled peristalsis mechanism. The pump works on a state-of-the-art technology i.e., iPRECIO, which can infuse fluids accurately via software programming. Market Activity: In 2022, a team of researchers from Novartis conducted tests on the iPRECIO SMP-310R Programmable pumps to study the correlation between pharmacokinetics (PK), target occupancy, and efficacy. 1 About Primtech Corporation: Primtech Corporation offers advanced life science solutions, especially the iPRECIO® Product Portfolio, facilitating efficient evaluation of molecule’s efficacy across different animal models. Their pumps are programmable, refillable, and implantable drug delivery devices, unleashing targeted drug delivery capabilities. Based on the data provided, it's clear that the advancement of programmable implantable pumps is ongoing with significant involvement from major industry players. Therefore, investing in thorough product benchmarking will enhance your product's potential for a successful launch in this field.

The ongoing advancements in Programmable Implantable Pumps, facilitating efficient drug delivery, present a promising field for exploration by medical device companies. The potential for efficient drug delivery and its promising impact on patient care highlight an exciting trajectory for innovation. For more comprehensive insights into this field, connect with Expertlancing Research Services. Together, let's navigate the possibilities and shape the future of medical technology.